Takeda's $4B immunology drug achieves first Phase 3 successes
Takeda's $4B immunology drug achieves first Phase 3 successes
Body unavailable. Use the original source.
Takeda's $4B immunology drug achieves first Phase 3 successes
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.